EGFR and glioblastoma: However, according to the abovementioned reports and the latest literature, as well as our data, we found that IDH-wt LGG and IDH-wt GBM may have differences in their prognoses and molecular features, such as TERT promoter mutation and EGFR amplification, which may lead to differences in treatment (12, 14).